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Dear Editor,
Mahboobi et al. should be commended for providing a 
clear and exhaustive review of the literature on the intrigu-
ing topic of the association of HCV infection with Lichen 
Planus (1). It is somewhat surprising, however, especially for 
a dermatologist such as myself, to read that the histopathol-
ogy of LP is nonspecific, but for cutaneous LP the specific-
ity is out of question. Actually, the reference that Mahboobi 
et al. cite for this point concerns oral LP, and most of their 
statements refer to the oral form of LP. The point is not im-
material, as it was the striking similarity of microscopic LP 
features with those of the liver affected by HCV-related active 
hepatitis that should suggest that a connection between the 
two conditions does exist. In both conditions, a T-cell infil-
trate impinges on the cells of the epithelial structure that 
are in direct contact with the corium: keratinocytes of the 
basal layer of the epidermis in LP and hepatocytes of the mu-
rallium of the hepatic lobe in active hepatitis. Also in both 
conditions,  T-cells  induce  apoptosis  of  the  epitheliocytes, 
disorganize the epithelium, and in some instances destroy 
it (erosive forms). Some time ago, when I described the first 
cases of a severe hepatic disease in patients with erosive LP 
(2), I was amazed not only by the striking similarity, but also 
by the fact that nobody had noticed it before. Certainly, not 
all  the  observations  and  epidemiological  studies  concur 
on the relationship between LP and HCV infection, and the 
geographical explanation may not be completely convinc-
ing. In addition to the explanation provided by Mahoobi et 
al. the possibility that OLP diagnoses might not always be 
correct cannot be overruled given the nonspecificity of OLP 
histopathology. Another epidemiological observation that 
cannot be neglected suggests a strict connection between 
LP and HCV infection. Specifically, this perspective has to do 
with a disease that is certainly HCV related: porphyria Cuta-
nea Tarda (PCT). All arguments that have been made for the 
LP-HCV connection have been made for PCT as well. Yet, the 
explanation that is universally accepted is the geographi-
cal one: PCT is prevalent in the regions in which HCV infec-
tion is prevalent, and nobody contests that HCV is the major 
etiologic factor of PCT. Even the combination of the three 
diseases has been reported (3). Certainly, HCV is not the sole 
cause of LP. In my view, LP is a cell-mediated immune reac-
tion to various agents, including viruses, the most impor-
tant of which are hepatotropic. In fact, LP is a relatively rare 
but well-recognized reaction to HBV vaccination (4). The real 
problem may simply be that most studies are retrospective, 
which makes it difficult to establish whether HCV exposure 
occurs prior to or after the onset of LP. The occurrence of LP 
reactions after HBV vaccination irrespective of the type of 
vaccine used, however, strongly suggests that LP occurs af-
ter the infection. I agree with the authors that no definite 
conclusion can be reached at this point and also with their 
statement that “screening of LP patients with ELISA is cost-
effective only with the presence of other risk factors”. The 
safety of patients and of oral specialists deserves attention 
in hyperendemic countries, and LP, regardless of the site af-
fected, provides an invaluable clue in this regard.
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